PCPLC: Percutaneous Cryoablation Peripheral Lung Cancer

• Sponsor: Shanghai Chest Hospital (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT02665390
• Collaborator: (none)
• Enrollment: 30
• Arm: 1
• Duration (Months): 47

Study Details

Study Description

Brief Summary

This study is focus on percutaneous cryoablation,which was for the treatment of medically inoperable Peripheral lung cancer.The patients who were agreed to attend the study will accept the operation. After the operations,they will follow up according to the plan.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer	Procedure: Percutaneous cryoablation	N/A

Detailed Description

The patients who were agreed to attend the study conclude early stage lung cancer and solitary metastatic lung cancer.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 30 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Percutaneous Cryoablation for the Treatment of Medically Inoperable Peripheral Lung Cancer
• Study Start Date: Feb 1, 2016
• Anticipated Primary Completion Date: Jan 1, 2018
• Anticipated Study Completion Date: Jan 1, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: treatment Patients who are medically inoperable peripheral lung cancer will enroll in this study.They will receive percutaneous cryoablation and follow-up according to schedule.	Procedure: Percutaneous cryoablation; Percutaneous cryoablation

Outcome Measures

Primary Outcome Measures

1. PFS [2 years]

Secondary Outcome Measures

1. OS [2 years]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

medically inoperable peripheral lung cancer Diameter no more than 3cm

Exclusion Criteria:

1. Refusal of participation

2. tendency to bleed to that can't receive percutaneous cryoablation.

3. Severe cardiopulmonary dysfunction and other indications that can't receive percutaneous cryoablation.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Shanghai Chest Hospital

Investigators

• Principal Investigator: Sun jiayuan, MD, Shanghai Chest Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

• Kawamura M, Izumi Y, Tsukada N, Asakura K, Sugiura H, Yashiro H, Nakano K, Nakatsuka S, Kuribayashi S, Kobayashi K. Percutaneous cryoablation of small pulmonary malignant tumors under computed tomographic guidance with local anesthesia for nonsurgical candidates. J Thorac Cardiovasc Surg. 2006 May;131(5):1007-13.
• Yamauchi Y, Izumi Y, Kawamura M, Nakatsuka S, Yashiro H, Tsukada N, Inoue M, Asakura K, Nomori H. Percutaneous cryoablation of pulmonary metastases from colorectal cancer. PLoS One. 2011;6(11):e27086. doi: 10.1371/journal.pone.0027086. Epub 2011 Nov 9.
• Zhang X, Tian J, Zhao L, Wu B, Kacher DS, Ma X, Liu S, Ren C, Xiao YY. CT-guided conformal cryoablation for peripheral NSCLC: initial experience. Eur J Radiol. 2012 Nov;81(11):3354-62. doi: 10.1016/j.ejrad.2012.04.035. Epub 2012 May 23.

• Responsible Party: Jiayuan Sun, Director, Endoscope Center, Shanghai Chest Hospita, Shanghai Chest Hospital
• ClinicalTrials.gov Identifier: NCT02665390
• Other Study ID Numbers: SHCHE201601
• First Posted: Jan 27, 2016
• Last Update Posted: Feb 12, 2016
• Last Verified: Feb 1, 2016

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Keywords provided by Jiayuan Sun, Director, Endoscope Center, Shanghai Chest Hospita, Shanghai Chest Hospital: lung cancer; Percutaneous cryoablation; treatment of medically inoperable
• Additional relevant MeSH terms: Lung Neoplasms

Study Results

No Results Posted as of Feb 12, 2016